Seeking Participants for a New CMT Clinical Trial: A Chance to Help Advance Treatment

by | Oct 1, 2024 | 0 comments

Seeking Participants for a New CMT Clinical Trial (for the US only):

A Chance to Help Advance Treatment! The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes, you may be eligible to participate in an exciting new clinical trial.

NMD Pharma, a biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the SYNAPSE-CMT Phase 2 trial. This trial will evaluate the safety, tolerability, and potential effectiveness of an investigational medication, NMD670, which could improve muscle strength and endurance in individuals with CMT.

What’s the Goal of the Study?

NMD670 may enhance communication between nerves and muscles where transmission is impaired, a common issue for people living with CMT. The hope is that this treatment will improve your strength, endurance, and overall daily functioning. By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future.

NextGen Precision Health, Missouri
Principal Investigator: W. David Arnold, MD
Contact: Neetha Gali | Email: [email protected] | Phone: (573) 882-3065

National Neuromuscular Research Institute, Texas
Principal Investigator: Yessar Hussain, MD
Contact: Stephanie Gonsoulin, RN, BSN | Email: [email protected] | Phone: (512) 920-0140 x210

Other locations, including those in New York, Boston, Kansas, Ohio, and Washington will be opening soon.

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news